<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00249444</url>
  </required_header>
  <id_info>
    <org_study_id>5086/6177R NIDA-09236-13</org_study_id>
    <secondary_id>P50DA009236</secondary_id>
    <secondary_id>P50DA009236-13</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00249444</nct_id>
  </id_info>
  <brief_title>Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression</brief_title>
  <official_title>A Placebo Controlled Trial of Mirtazapine for Patients With Depression and Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many substance dependent individuals also suffer from depression. Past research suggests that
      antidepressant medication is helpful in treating such individuals. This study will determine
      the effectiveness of mirtazapine, an antidepressant medication, in treating cocaine dependent
      individuals who also suffer from depression. This study includes free treatment for cocaine
      dependence that includes medication and a behavioral intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine abuse and depression often occur together. Individuals suffering from both are
      usually not able to quit abusing cocaine. Past research conducted on alcohol dependent
      individuals also suffering from depression showed that these individuals were able to
      successfully quit drinking with the addition of an antidepressant medication. Mirtazapine is
      a medication currently used to treat depression. This study will evaluate the efficacy of
      mirtazapine, used in combination with behavioral therapy, in treating cocaine dependent
      individuals who also suffer from depression.

      Participants in this 8-week trial will be randomly assigned to receive either mirtazapine or
      placebo. Prior to starting medication treatment, participants will undergo an initial 2-week
      phase consisting of psychosocial and behavioral therapy. The purpose of this lead-in phase is
      to achieve initial reduction or abstinence in cocaine use, while observing cocaine withdrawal
      symptoms and mood changes associated with depression. During these first 2 weeks,
      participants will attend three study visits each week, at which time they will participate in
      motivational interviews and cognitive behavioral relapse prevention therapy. During this
      phase, participants who successfully remain abstinent from cocaine use will be rewarded with
      high-value monetary vouchers.

      Upon completing the lead-in phase, participants will be randomly assigned to receive either
      mirtazapine or placebo. Participants will attend study visits twice each week for 8 weeks.
      Mood and drug use will be evaluated at each study visit. Cognitive behavioral relapse
      prevention therapy will continue throughout the study. In addition, participants will earn
      low-value monetary vouchers contingent on cocaine abstinence.

      At the end of Week 8, participants will enter the lead-out phase. At this time, those
      participants whose mood has significantly improved will be able to continue treatment for an
      additional 8 weeks. Participants whose mood has not shown improvement will be tapered off
      their assigned medication treatment and will be offered treatment with an alternative
      medication. Following completion of the lead-out phase, all participants will be referred for
      continuing care in the community.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Abstinence During Last Three Weeks of Study</measure>
    <time_frame>measured daily by self report and confimed by urine toxicology for 8 weeks of the trial or length of study participation</time_frame>
    <description>measured daily by self report and confimed by urine toxicology for 8 weeks of the trial or length of study participation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression Score on Hamilton - Depression 25 Item</measure>
    <time_frame>End of 8 week study or last week of participation</time_frame>
    <description>Participants those who had a 50% decrease in HAM-D scores from baseline at end of study. The outcome measured is 50% drop in Hamilton score at week 8 or last week of study participation compared to baseline. We looked at the difference between baseline score and score at week 8 or last week of study participation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Cocaine Dependence</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Mirtazapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Mirtazapine</description>
    <arm_group_label>Mirtazapine</arm_group_label>
    <other_name>Remeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for current cocaine dependence

          -  Currently seeking treatment for cocaine dependence

          -  Used cocaine for at least one day per 2-week period in the month prior to study entry

          -  Meets DSM-IV criteria for current major depression or dysthymia syndrome

          -  Scores greater than 12 on the Baseline 21 Hamilton Depression Scale

          -  Ages 18-60

        Exclusion Criteria:

          -  Meets DSM-IV criteria for past mania (e.g., bipolar disorder), schizophrenia, or any
             psychotic disorder other than transient psychosis due to drug abuse

          -  Scores less than 11 on the Baseline 21 Hamilton Depression Scale

          -  History of seizures

          -  History of an allergic reaction to mirtazapine

          -  Chronic organic mental disorder

          -  Current suicidal risks or any history of suicidal behavior

          -  Pregnant, breastfeeding, or unwilling to use an adequate method of contraception for
             the duration of the study

          -  Unstable physical disorders, including high blood pressure, acute hepatitis, or
             diabetes

          -  Coronary vascular disease as indicated by history, or suspected by abnormal
             electrocardiogram, or history of cardiac symptoms

          -  Cardiac conduction system disease, as indicated by an electrocardiogram QRS duration
             greater than 0.11

          -  History of failure to respond to a previous trial of mirtazapine

          -  Currently taking psychotropic medication

          -  Meets DSM-IV criteria for opioid or sedative-hypnotic dependence

          -  Meets DSM-IV criteria for alcohol dependence with evidence of clinically significant
             physiological dependence in need of medically supervised detoxification

          -  Current alcohol or marijuana dependence identified as the main problem for seeking
             treatment; individuals with alcohol or marijuana dependence (without significant
             physiological dependence) and cocaine dependence are eligible, as long as cocaine is
             identified as the primary substance problem for which they are seeking treatment

          -  History of neutropenia (&lt; 500 granulocytes /cc) or Agranulocytosis (&lt;500
             granulocytes/cc) with fever, infection. Concurrent intake of medications with possible
             neutropenic effects: chlorpromazine, carbamazepine, clozapine, chemotherapeutic drugs,
             immunosuppressant medications, interferons, ganciclovir, protease inhibitors.

          -  Patients not able to meet attendance requirement of 4/6 visits during the lead-in
             period.

          -  Supplemental exclusion criteria for cold pressor test (CPT): history of frostbite,
             open cut or sore on foot to be immersed, history of Raynaud's phenomenon.

          -  Supplemental exclusion criteria for CPT: hypertension (BP less than or equal 140/90)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfrid Raby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Foundation for Mental Hygiene, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stars.columbia.edu</url>
    <description>service website</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2005</study_first_submitted>
  <study_first_submitted_qc>November 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2005</study_first_posted>
  <results_first_submitted>April 12, 2016</results_first_submitted>
  <results_first_submitted_qc>September 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2017</results_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cocaine dependence</keyword>
  <keyword>mirtazipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Mianserin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There was a 2 week (no medication) lead-in period prior to randomization. To be randomized, patients had to attend at least 4 of 6 clinic visits, and submit at least 4 of 6 urine samples for toxicology during these two weeks. 86 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mirtazapine</title>
          <description>Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.
Mirtazapine: Mirtazapine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo
Placebo: placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliant</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>life event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mirtazapine</title>
          <description>Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.
Mirtazapine: Mirtazapine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo
Placebo: placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="7.6"/>
                    <measurement group_id="B2" value="42.9" spread="8.4"/>
                    <measurement group_id="B3" value="42.8" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Abstinence During Last Three Weeks of Study</title>
        <description>measured daily by self report and confimed by urine toxicology for 8 weeks of the trial or length of study participation</description>
        <time_frame>measured daily by self report and confimed by urine toxicology for 8 weeks of the trial or length of study participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirtazapine</title>
            <description>Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.
Mirtazapine: Mirtazapine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Abstinence During Last Three Weeks of Study</title>
          <description>measured daily by self report and confimed by urine toxicology for 8 weeks of the trial or length of study participation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Depression Score on Hamilton - Depression 25 Item</title>
        <description>Participants those who had a 50% decrease in HAM-D scores from baseline at end of study. The outcome measured is 50% drop in Hamilton score at week 8 or last week of study participation compared to baseline. We looked at the difference between baseline score and score at week 8 or last week of study participation.</description>
        <time_frame>End of 8 week study or last week of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirtazapine</title>
            <description>Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.
Mirtazapine: Mirtazapine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Depression Score on Hamilton - Depression 25 Item</title>
          <description>Participants those who had a 50% decrease in HAM-D scores from baseline at end of study. The outcome measured is 50% drop in Hamilton score at week 8 or last week of study participation compared to baseline. We looked at the difference between baseline score and score at week 8 or last week of study participation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during 2 week lead-in and 8 weeks of trial or course of study participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mirtazapine</title>
          <description>Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.
Mirtazapine: Mirtazapine</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo
Placebo: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>appetite increase</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early cocaine responders were the most likely to achieve three weeks of continuous abstinence. 20% of patients on mirtazapine did not have any detectable blood level, therefore, poor compliance may have prevented detection of a medication effect.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Wilfrid Raby</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-923-3031</phone>
      <email>rabywil@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

